Coherus Oncology (CHRS) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nkarta (NKTX) has outperformed Coherus Oncology (CHRS) over the past year, gaining 6.2% versus a loss of 39.2%. Over five years, NKTX leads with a -87.9% price change compared with -93.7% for CHRS. Coherus Oncology is the larger company by market cap ($165.3 million vs $159.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | NKTX |
|---|---|---|
| Share price | $1.07 | $2.22 |
| Market cap | $165.32M | $159.01M |
| 1-day change | +5.94% | -2.20% |
| YTD return | -24.65% | +20.00% |
| 1-year return | -39.20% | +6.22% |
| 5-year return | -93.71% | -87.90% |
| EPS (TTM) | $-1.25 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.62 | $3.72 |
| 52-week low | $0.974 | $1.70 |
| Distance from 52-week high | -59.10% | -40.32% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +624.30% | +387.84% |
| Average volume | 1.16M | 613.16K |
| Shares outstanding | 154.50M | 71.62M |
| Employees | 144 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NKTX has outperformed CHRS by 45.4 percentage points over the past year.
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
CHRS vs NKTX FAQ
Which is bigger, Coherus Oncology or Nkarta?
Coherus Oncology (CHRS) is larger, with a market capitalization of $165.32M compared with $159.01M for Nkarta (NKTX).
Which stock has performed better over the past year, CHRS or NKTX?
NKTX returned +6.22% over the past 12 months, compared with -39.20% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and Nkarta in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Coherus Oncology and Biotechnology: Pharmaceutical Preparations for Nkarta.